Palisade Bio (PALI) Fundamentals 2026 — Revenue Analysis | SniperIQ
Palisade Bio (PALI) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Palisade Bio (PALI) has a market capitalization of approximately
Palisade Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Palisade Bio runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Palisade Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Palisade Bio carries a debt-to-equity ratio of 0.00x and a current ratio of 23.71x, with a market beta of 1.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Palisade Bio (PALI) the key facts are: market cap
Get Palisade Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.